RE: Potential for Re-Rating10 Jun 2020 08:50
Lets stick to the facts, as some appear to be hell bent on providing their personal views. So what is know to the market/ investors:
Avion and ImmuPharma were set to meet with the US Food and Drug Administration (FDA) in the first quarter, to discuss guidance on a new optimised international phase 3 trial protocol.
Positive discussions were also said to be ongoing with a number of potential commercial partners of Lupuzor outside of the United States.
This news is imminent and in my view an update will be provided before the AGM, which is to take place next Thursday.